Shanghai Model Organisms Center, Inc. (SHA:688265)
34.77
-0.85 (-2.39%)
Jun 2, 2026, 3:00 PM CST
SHA:688265 Revenue
Shanghai Model Organisms Center had revenue of 99.92M CNY in the quarter ending March 31, 2026, with 13.03% growth. This brings the company's revenue in the last twelve months to 432.55M, up 11.85% year-over-year. In the year 2025, Shanghai Model Organisms Center had annual revenue of 421.02M with 10.44% growth.
Revenue (ttm)
432.55M
Revenue Growth
+11.85%
P/S Ratio
6.08
Revenue / Employee
510.08K
Employees
749
Market Cap
2.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 421.02M | 39.78M | 10.44% |
| Dec 31, 2024 | 381.24M | 14.69M | 4.01% |
| Dec 31, 2023 | 366.55M | 63.58M | 20.99% |
| Dec 31, 2022 | 302.97M | 27.70M | 10.06% |
| Dec 31, 2021 | 275.27M | 79.08M | 40.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beijing Kawin Technology Share-Holding | 1.30B |
| Shanghai Universal Biotech | 1.13B |
| Zhejiang East Asia Pharmaceutical | 1.01B |
| Shandong Sito Bio-technology | 954.76M |
| Jilin Jian Yisheng Pharmaceutical | 659.66M |
| Zhejiang Shouxiangu Pharmaceutical | 625.30M |
| Suzhou Fushilai Pharmaceutical | 412.51M |
| Yantai Zhenghai Biotechnology | 347.75M |